Aspergillus fumigatus endocarditis in a pediatric liver transplant recipient: Favorable outcome without cardiac surgery

Pediatric Transplantation

Volumn 13, Issue 5, 2009, Pages 636-640

  Mourier, Olivia ^a   Durand, Philippe ^a   Lambert, Virginie ^a   Bretagne, Stéphane ^b   Maurage, Chantal ^c   Branchereau, Sophie ^a   Bernard, Olivier ^a   Jacquemin, Emmanuel ^a  

^a BICÊTRE HOSPITAL   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c Centre de Pediatrie Clocheville   (France)

Author keywords

Antifungal therapy; Aspergillus fumigatus; Children; Endocarditis; Liver transplantation

Indexed keywords

AMPHOTERICIN B; BASILIXIMAB; CASPOFUNGIN; FLUCONAZOLE; TACROLIMUS; VORICONAZOLE;

ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CASE REPORT; DOPPLER ECHOCARDIOGRAPHY; ENDOCARDITIS; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; OUTCOME ASSESSMENT; POSTOPERATIVE INFECTION;

ADMINISTRATION, ORAL; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; ECHOCARDIOGRAPHY, DOPPLER; ENDOCARDITIS; FEMALE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; LIVER TRANSPLANTATION; POLYMERASE CHAIN REACTION; POSTOPERATIVE COMPLICATIONS; TIME FACTORS; TREATMENT OUTCOME;

EID: 67651180881     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2008.00929.x     Document Type: Article

References (23)

1. Paterson DL, Singh N. Invasive aspergillosis in transplant recipients. Medicine (Baltimore) 1999 : 78 : 123 128.
2. Singh N, Arnow PM, Bonham A, et al. Invasive aspergillosis in liver transplant recipients in the 1990s. Transplantation 1997 : 64 : 716 720. (Pubitemid 27407098)
3. Gumbo T, Taege AJ, Mawhorter S, et al. Aspergillus valve endocarditis in patients without prior cardiac surgery. Medicine (Baltimore) 2000 : 79 : 261 268.
4. Fortun J, Martin-Davila P, Moreno S, et al. Risk factors for invasive aspergillosis in liver transplant recipients. Liver Transplant 2002 : 8 : 1065 1070.
5. Roux JP, Koussa A, Cajot MA, et al. Les endocardites aspergillaires primitives. Ann Chir 1992 : 46 : 110 115.
6. Collins LA, Samore MH, Roberts MS, et al. Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J Infect Dis 1994 : 170 : 644 652.
7. Woods GL, Wood RP, Shaw BW Jr. Aspergillus endocarditis in patients without prior cardiovascular surgery: Report of a case in liver transplant recipient and review. Rev Infect Dis 1989 : 11 : 263 272.
8. Vassiloyanakopoulos A, Falagas ME, Allamani M, Michalopoulos A. Aspergillus fumigatus tricuspid native valve endocarditis in a non-intravenous drug user. J Med Microbiol 2006 : 55 : 635 638.
9. Kusne S, Torre-Cisneros J, Manez R, et al. Factors associated with invasive lung aspergillosis and the significance of positive aspergillus culture after liver transplantation. J Infect Dis 1992 : 166 : 1379 1383.
10. Rao K, Saha V. Medical management of aspergillus flavus endocarditis. Pediatr Hematol Oncol 2000 : 17 : 425 427.
11. Rubio Alvarez J, Sierra Quiroga J, Rubio Taboada C, Fernandez Gonzalez A, Garcia-Bengochea J. Cardiac aspergillosis with pedunculated mass in the left ventricle. Tex Heart Inst J 2004 : 31 : 439 441.
12. Kotanidou AN, Zakynthinos E, Andrianakis I, et al. Aspergillus endocarditis in native valve after Amphotericin B treatment. Ann Thorac Surg 2004 : 78 : 1453 1455.
13. Vianna R, Misra V, Fridell JA, Goldman M, Mangus RS, Tector J. Survival after disseminated invasive aspergillosis in a multivisceral transplant recipient. Transplant Proc 2007 : 39 : 305 307.
14. Patterson TF, Miniter P, Patterson JE, Rappeport JM, Andriole VT. Aspergillus antigen detection in the diagnostis of invasive aspergillosis. J Infect Dis 1995 : 171 : 1553 1558.
15. Fortun J, Martin-Davila P, Alvarez ME, et al. Aspergillus antigenemia sandwich-enzyme immunoassay test as a serodiagnostic method for invasive aspergillosis in liver transplant recipients. Transplantation 2001 : 71 : 145 149.
16. Klingspor L, Jalai S. Molecular detection and identification of candida and aspergillus spp. from clinical samples using real time PCR. Clin Microbiol Infect 2006 : 12 : 745 753.
17. Shabereiter-Gurtner C, Selitsch B, Rotter ML, Hirschl AM, Willinger B. Development of novel-real time PCR assays for detection and differentiation of eleven medically important Aspergillus and Candida species in clinical specimens. J Clin Microbiol 2007 : 45 : 906 914.
18. Ascioglu S, Rex JH, De Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis 2002 : 34 : 7 14.
19. Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D. Pharmacokinetics and safety of voriconazole following intravenous to oral-dose escalation regimens. Antimicrob Agents Chemother 2002 : 46 : 2546 2553.
20. Dannaoui E, Lortholary O, Dromer F. In vitro evaluation of double and triple combinations of antifungal drugs against aspergillus fumigatus and aspergillus terreus. Antimicrob Agents Chemother 2004 : 48 : 970 978.
21. Maccallum DM, Whyte JA, Odds JC. Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis. Antimicrob Agents Chemother 2004 : 49 : 3697 3701.
22. Marr K. Combination antifungal therapy: Where are we now and where are we going? Oncology 2004 : 18 : S24 S29.
23. Maertens J, Verhaegen J, Demuynck H, et al. Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for haematological patients at risk for invasive aspergillosis. J Clin Microbiol 1999 : 37 : 3223 3228.